In case of larger nanobody drug formats, opsonization and subsequent recognition and uptake by the reticuloendothelial system (RES) may occur, leading to hepatic clearance of these therapeutic ...

is developing drug-conjugated vectors that bind to BBB receptors with high-affinity, triggering transport into and across cells (Fig. 1). “We are developing peptide and nanobody vectors that ...

Sanofi is to pay Ablynx up to €2.4 billion to develop drugs for immune-related inflammatory diseases based on the biotech’s nanobody technology. The Paris-headquartered pharma firm is ...

To address this challenge, researchers at the University of Minnesota and the Midwest Antiviral Drug Discovery (AViDD) Center have developed the first nanobody-based inhibitors targeting the Ebola ...

The drug is a nanobody, a molecule around one-tenth the size of a regular antibody derived from camelid species such as the llama. Proponents say they can offer greater stability, smaller size ...

New nanobody approach shows early promise against ... for which there are two U.S. approved human antibody drugs - Ebanga from Ridgeback Biotherapeutics and Inmazeb from Regeneron Pharmaceuticals ...

SHL Medical, a world-leading provider of advanced drug delivery solutions, announced that it has signed a collaboration ...

A novel nanobody-based immunosensor ... and exhibits great potential for point-of-care testing, therapeutic drug monitoring, and environmental applications using paper-based devices.